2. Search Result
Search Result
Results for "

Aβ40

" in MedChemExpress (MCE) Product Catalog:

48

Inhibitors & Agonists

1

Biochemical Assay Reagents

5

Peptides

2

Inhibitory Antibodies

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-11102
    RO4929097
    15+ Cited Publications

    		 γ-secretase Notch Neurological Disease Cancer
    RO4929097 is an orally active γ secretase inhibitor with an IC50 of 4 nM, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively .
    RO4929097
  • HY-10974
    MK-0752
    10+ Cited Publications

    		 γ-secretase Neurological Disease Cancer
    MK-0752 is a potent, orally active and specific γ-secretase inhibitor, showing dose-dependent reduction of Aβ40 with an IC50 of 5 nM in human SH-SY5Y cells. MK-0752 crosses the blood-brain barrier. MK-0752 reduces newly generated CNS Aβ in vivo .
    MK-0752
  • HY-16759
    Verubecestat
    5 Publications Verification

    MK-8931

    		 Beta-secretase Neurological Disease
    Verubecestat (MK-8931) is an orally active, high-affinity BACE1 and BACE2 inhibitor with Ki values of 2.2 nM and 0.38 nM. Verubecestat effectively reduces Aβ40 and has the potential for Alzheimer's Disease .
    Verubecestat
  • HY-50845
    Avagacestat
    2 Publications Verification

    BMS-708163

    		 γ-secretase Notch Cancer
    Avagacestat (BMS-708163) is a potent inhibitor of γ-secretase, with IC50s of 0.27 nM and 0.30 nM for Aβ42 and Aβ40 inhibition; Avagacestat (BMS-708163) also inhibits NICD (Notch IntraCellular Domain) with IC50 of 0.84 nM and shows weak inhibition of CYP2C19, with IC50 of 20 μM. Avagacestat can be used for Alzheimer disease research.
    Avagacestat
  • HY-12723
    Apomorphine
    5+ Cited Publications

    (-)-Apomorphine

    		 Dopamine Receptor Monoamine Oxidase Reactive Oxygen Species (ROS) JNK ERK Amyloid-β Tau Protein MMP Neurological Disease Inflammation/Immunology Endocrinology Cancer
    Apomorphine ((-)-Apomorphine) is a potent dopamine receptor agonist. Apomorphine also inhibit MAO-A and MAO-B. Apomorphine exerts neuroprotective effect and can relax rat corpus cavernosum. Apomorphine can inhibit ROS production, DNA fragmentation and inibit JNK and ERK1/2 phosphorylation. Apomorphine can enhance degradation of intracellular Aβ40 and Aβ42, reduces tau protein levels and inhibit MMP-9 expression. Apomorphine is a highly potent radical scavenger and iron chelator. Apomorphine can be used for the researches of dementia, parkinson's disease, alzheimer disease, breast carcinoma, and erectile dysfunction .
    Apomorphine
  • HY-10009
    Semagacestat
    10+ Cited Publications

    LY450139

    		 γ-secretase Amyloid-β Notch Neurological Disease
    Semagacestat is a γ-secretase inhibitor, inhibits β-amyloid (Aβ42), Aβ38 and Aβ40 with IC50s of 10.9, 12 and 12.1 nM, respectively; also inhibits Notch signaling with IC50 of 14.1 nM. Semagacestat can be used for the research of alzheimer's disease .
    Semagacestat
  • HY-16659
    EHT 1864
    Maximum Cited Publications
    22 Publications Verification

    		 Ras Neurological Disease Cancer
    EHT 1864 is an inhibitor of Rac family small GTPases. EHT 1864 directly binds and impairs the ability of this small GTPase to engage critical downstream effectors required for growth transformation. The Kd values are 40, 50, 60, and 230 nM for Rac1, Rac1b, Rac2 and Rac3, respectively. EHT 1864 also potently inhibits other Rac-dependent transformation processes, Tiam1- and Ras-mediated growth transformation. EHT 1864 prevents Aβ 40 and Aβ 42 production in vivo. EHT 1864 dependently suppresses the release of migrasomes from podocytes induced by LPS, PAN, or HG .
    EHT 1864
  • HY-137131
    DC-Chol hydrochloride

    DC-Cholesterol hydrochloride

    		 Amyloid-β Liposome IFNAR Interleukin Related Neurological Disease Inflammation/Immunology
    DC-Chol hydrochloride is a cationic lipid. DC-Chol hydrochloride could inhibit Aβ40 fibril formation under appropriate experimental conditions. DC-Chol hydrochloride strongly inhibits amyloidogenesis of oxidized hCT in a dose-dependent manner. DC-Chol hydrochloride induces the production of Th1 (IL-2 and IFN-γ) and Th2 (IL-5) cytokines. DC-Chol hydrochloride can enhance the body's immune response to antigens. DC-Chol hydrochloride is used as a gene delivery vector. DC-Chol hydrochloride can be used in research in areas such as hepatitis B vaccines to improve vaccine immunity .
    DC-Chol hydrochloride
  • HY-14399
    Itanapraced
    1 Publications Verification

    CHF5074; CSP-1103

    		 γ-secretase Apoptosis Neurological Disease
    Itanapraced (CHF5074) is an orally active γ-secretase modulator and a non-steroidal anti-inflammatory derivative. Itanapraced reduces Aβ42 and Aβ40 secretion with IC50 values of 3.6 and 18.4 μM, respectively. Itanapraced inhibits cell apoptosis of hippocampal neurons induced by oxygen and glucose deprivation (OGD). Itanapraced can be used for the research of Alzheimer's disease .
    Itanapraced
  • HY-W176557
    TGN-073

    		Aquaporin Neurological Disease
    TGN-073 is a aquaporin 4 (AQP4) modulator, as well as an orally available, blood-brain barrier-permeable agent. TGN-073 increases the uptake and distribution of brain MRI tracers in the brain parenchyma and reduces the levels of insoluble amyloid-β 40 and β 42. TGN-073 can be used in research related to Alzheimer's disease, dementia, traumatic brain injury and pain .
    TGN-073
  • HY-120789
    PF-06648671

    		γ-secretase Neurological Disease
    PF-06648671 is a novel, brain-penetrable, and orally active γ-secretase modulator (GSM). PF-06648671 reduces Aβ42 and Aβ40, with concomitant increases in Aβ37 and Aβ38 in vitro. PF-06648671 is used for the study of Alzheimer’s disease .
    PF-06648671
  • HY-101087
    Benzenesulphonamide

    		Carbonic Anhydrase Amyloid-β Reactive Oxygen Species (ROS) Neurological Disease Inflammation/Immunology Cancer
    Benzenesulphonamide (Compound 1) is a carbonic anhydrase inhibitor. Benzenesulphonamide exhibits CA II inhibitory activity. Benzenesulphonamide reduces ROS and improves the gene expression of amyloid-β40 and 42. Benzenesulphonamide is beneficial for Alzheimer's disease. Benzenesulphonamide derivatives have anticancer, anti-inflammatory, and anticonvulsant activities. Benzenesulphonamide can be used in the research of Alzheimer's disease, epilepsy, inflammatory diseases, leukemia, melanoma, lung cancer, and colon cancer .
    Benzenesulphonamide
  • HY-14175
    Begacestat

    GSI-953

    		 γ-secretase Neurological Disease
    Begacestat (GSI-953) is a selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase (IC50Aβ40=15 nM) for the treatment of Alzheimer's disease .
    Begacestat
  • HY-P990301
    Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2)

    		Amyloid-β Neurological Disease
    Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) is a mouse-derived IgG2b λ type antibody inhibitor, targeting to Amyloid-beta. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) recognizes unaggregated, oligomeric or fibrillar forms of Aβ42 and unaggregated Aβ40. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) is selective for human Aβ42 over Aβ40, but not amyloid precursor protein (APP). Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) can immunostain human or rat and mouse tissue. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) can be used for detections of western blot, immunohistochemistry, immunofluorescence, immunoprecipitation and ELISA .
    Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2)
  • HY-117482
    BPN-15606

    		γ-secretase Neurological Disease
    BPN-15606 is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 and Aβ40 by SHSY5Y neuroblastoma cells with IC50 values of 7 nM and 17nM, respectively. BPN-15606 lowers Aβ42 and Aβ40 levels in the central nervous system of rats and mice. BPN-15606 has acceptable PK/PD properties, including bioavailability, half-life, and clearance .
    BPN-15606
  • HY-W594851
    Biphenyl-3′,3,4,4′-tetrol

    BPT

    		 Amyloid-β Neurological Disease
    Biphenyl-3′,3,4,4′-tetrol (BPT) is a potent Aβ40 aggregation inhibitor. Biphenyl-3′,3,4,4′-tetrol (BPT) can be used in the study of neurodegenerative diseases such as Alzheimer's disease .
    Biphenyl-3′,3,4,4′-tetrol
  • HY-153986
    AEP-IN-2

    		Cathepsin Neurological Disease
    AEP-IN-2 is an asparagine endopeptidase (AEP) inhibitor via block AEP cleavage of APP and Tau. AEP-IN-2 has oral activity and decreases Aβ40 and Aβ42 and p-Tau levels .
    AEP-IN-2
  • HY-114508
    Dihydrochalcone

    3-Phenylpropiophenone; β-Phenylpropiophenone

    		 Amyloid-β Neurological Disease
    Dihydrochalcone (3-Phenylpropiophenone) is a Aβ aggregation inhibitor. Dihydrochalcone destabilizes Aβ17-42 protofibrils by disrupting the β-sheet of β1 region. Dihydrochalcone destabilizes both U-shaped Aβ40/Aβ42 protofibrils and S-shaped Aβ42 protofibrils by binding to the protofibril cavity. Dihydrochalcone is the main component of daemonorops draco tree .
    Dihydrochalcone
  • HY-P1894
    β-Amyloid Protein Precursor 770 (135-155)

    		Amyloid-β Neurological Disease
    β-Amyloid Protein Precursor 770 (135-155) is a peptide of amyloid precursor protein isoform (APP 770). APP 770 produces Aβ40/42 .
    β-Amyloid Protein Precursor 770 (135-155)
  • HY-12938
    AMG-8718

    		Beta-secretase Neurological Disease
    AMG-8718 is a potent, selective and orally active BACE1 inhibitor with IC50 values of 0.0007, 0.005 µM for BACE1 and BACE2, respectively. AMG-8718 significantly decreases Aβ40 levels in the CSF and brain .
    AMG-8718
  • HY-P1894A
    β-Amyloid Protein Precursor 770 (135-155) TFA

    		Amyloid-β Neurological Disease
    β-Amyloid Protein Precursor 770 (135-155) TFA is a peptide of amyloid precursor protein isoform (APP 770). APP 770 produces Aβ40/42 .
    β-Amyloid Protein Precursor 770 (135-155) TFA
  • HY-16759B
    Verubecestat tosylate

    MK-8931 tosylate

    		 Beta-secretase Neurological Disease
    Verubecestat tosylate is an orally active, high-affinity BACE1 and BACE2 inhibitor with Ki values of 2.2 nM and 0.38 nM. Verubecestat tosylate effectively reduces Aβ40 and has the potential for Alzheimer's Disease .
    Verubecestat tosylate
  • HY-117236
    GSI-136

    		γ-secretase Neurological Disease
    GSI-136 is an inhibitor of γ-secretase with an IC50 of 3 nM. GSI-136 can lead to a dose-dependent reduction of Aβ40 levels in diethylamine-extracted brain homogenates of C57BL/6 mice. GSI-136 can be studied in medicinal chemistry and Alzheimer's disease research .
    GSI-136
  • HY-149272
    tau/Aβ40 aggregation-IN-1

    		Tau Protein Amyloid-β Cholinesterase (ChE) Neurological Disease
    tau/Aβ40 aggregation-IN-1 (Compound 20) is a tau and Aβ40 aggregation inhibitor with IC50s of 1.8 μM and 1.3 μM, respectively .
    tau/Aβ40 aggregation-IN-1
  • HY-117482A
    BPN-15606 besylate

    		γ-secretase Neurological Disease
    BPN-15606 besylate is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 and Aβ40 by SHSY5Y neuroblastoma cells with IC50 values of 7 nM and 17nM, respectively. BPN-15606 besylate lowers Aβ42 and Aβ40 levels in the central nervous system of rats and mice. BPN-15606 besylate has acceptable PK/PD properties, including bioavailability, half-life, and clearance .
    BPN-15606 besylate
  • HY-123228
    CHF5022

    		Amyloid-β Neurological Disease
    CHF5022 is an inhibitor of Aβ42 secretion (IC50=92 μM). CHF5022 retains a modest activity on Aβ40 at non-cytotoxic concentrations (−22.2±4.8% at 100 μM) .
    CHF5022
  • HY-16759A
    Verubecestat TFA
    5 Publications Verification

    MK-8931 TFA

    		 Beta-secretase Neurological Disease
    Verubecestat (MK-8931) TFA is an orally active, high-affinity BACE1 and BACE2 inhibitor with Ki values of 2.2 nM and 0.38 nM. Verubecestat TFA effectively reduces Aβ40 and has the potential for Alzheimer's Disease .
    Verubecestat TFA
  • HY-155304
    BuChE-IN-8

    		Cholinesterase (ChE) Neurological Disease
    BuChE-IN-8 (compound 19c) is a butyrylcholinesterase (BuChE) inhibitor with an IC50 of 559 nM. BuChE-IN-8 possesses human β-secretase (BACE1) and Aβ40 aggregation inhibitory activities. BuChE-IN-8 has significant antiamnesic properties .
    BuChE-IN-8
  • HY-14175R
    Begacestat (Standard)

    GSI-953 (Standard)

    		 γ-secretase Reference Standards Neurological Disease
    Begacestat (Standard) is the analytical standard of Begacestat. This product is intended for research and analytical applications. Begacestat (GSI-953) is a selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase (IC50Aβ40=15 nM) for the treatment of Alzheimer's disease .
    Begacestat (Standard)
  • HY-10143
    LY-2434074

    		Beta-secretase Amyloid-β Neurological Disease
    LY-2434074 is a selective β-secretase (BACE) inhibitor with an IC50 <100 nM. LY-2434074 can inhibit amyloid-β (Aβ40 and Aβ42) production. LY-2434074 can be used for the research of neurological disease, such as Alzheimer's disease .
    LY-2434074
  • HY-16759R
    Verubecestat (Standard)

    MK-8931 (Standard)

    		 Beta-secretase Reference Standards Neurological Disease
    Verubecestat (Standard) is the analytical standard of Verubecestat. This product is intended for research and analytical applications. Verubecestat (MK-8931) is an orally active, high-affinity BACE1 and BACE2 inhibitor with Ki values of 2.2 nM and 0.38 nM. Verubecestat effectively reduces Aβ40 and has the potential for Alzheimer's Disease .
    Verubecestat (Standard)
  • HY-10975
    MK-0752 sodium

    		γ-secretase Neurological Disease Cancer
    MK-0752 sodium is a potent, orally active and specific γ-secretase inhibitor, showing dose-dependent reduction of Aβ40 with an IC50 of 5 nM in human SH-SY5Y cells. MK-0752 sodium crosses the blood-brain barrier. MK-0752 sodium reduces newly generated CNS Aβ in vivo .
    MK-0752 sodium
  • HY-149273
    hBChE-IN-1

    		Cholinesterase (ChE) Amyloid-β Tau Protein Neurological Disease
    hBChE-IN-1 (compound 4), a quinolizidinyl derivative, is a potent hBChE inhibitor (IC50=7 nM) and highly selective over hAChE. hBChE-IN-1 shows inhibitory activity against tau and Aβ40 protein aggregation, with IC50 values of 20 and 4.3 μM, respectively. hBChE-IN-1 can be used for Alzheimer's disease research .
    hBChE-IN-1
  • HY-10009R
    Semagacestat (Standard)

    LY450139 (Standard)

    		 Reference Standards γ-secretase Amyloid-β Notch Neurological Disease
    Semagacestat (Standard) is the analytical standard of Semagacestat. This product is intended for research and analytical applications. Semagacestat is a γ-secretase inhibitor, inhibits β-amyloid (Aβ42), Aβ38 and Aβ40 with IC50s of 10.9, 12 and 12.1 nM, respectively; also inhibits Notch signaling with IC50 of 14.1 nM. Semagacestat can be used for the research of alzheimer's?disease .
    Semagacestat (Standard)
  • HY-P3781
    (Met(O)35)-Amyloid β-Protein (1-42)

    		Amyloid-β Neurological Disease
    (Met(O)35)-Amyloid β-Protein (1-42) is the oxidation form of Met35 in Aβ42. (Met(O)35)-Amyloid β-Protein (1-42) can yield an oligomer size distribution characteristic of Aβ40. (Met(O)35)-Amyloid β-Protein (1-42) can be used in the research of Alzheimer’s disease (AD) .
    (Met(O)35)-Amyloid β-Protein (1-42)
  • HY-50845R
    Avagacestat (Standard)

    BMS-708163 (Standard)

    		 γ-secretase Notch Reference Standards Cancer
    Avagacestat (Standard) is the analytical standard of Avagacestat. This product is intended for research and analytical applications. Avagacestat (BMS-708163) is a potent inhibitor of γ-secretase, with IC50s of 0.27 nM and 0.30 nM for Aβ42 and Aβ40 inhibition; Avagacestat (BMS-708163) also inhibits NICD (Notch IntraCellular Domain) with IC50 of 0.84 nM and shows weak inhibition of CYP2C19, with IC50 of 20 μM. Avagacestat can be used for Alzheimer disease research.
    Avagacestat (Standard)
  • HY-14399R
    Itanapraced (Standard)

    CHF5074 (Standard); CSP-1103 (Standard)

    		 γ-secretase Apoptosis Reference Standards Neurological Disease
    Itanapraced (Standard) is the analytical standard of Itanapraced. This product is intended for research and analytical applications. Itanapraced (CHF5074) is an orally active γ-secretase modulator and a non-steroidal anti-inflammatory derivative. Itanapraced reduces Aβ42 and Aβ40 secretion with IC50 values of 3.6 and 18.4 μM, respectively. Itanapraced inhibits cell apoptosis of hippocampal neurons induced by oxygen and glucose deprivation (OGD). Itanapraced can be used for the research of Alzheimer's disease .
    Itanapraced (Standard)
  • HY-101087R
    Benzenesulphonamide (Standard)

    		Reference Standards Carbonic Anhydrase Amyloid-β Reactive Oxygen Species (ROS) Neurological Disease Inflammation/Immunology Cancer
    Benzenesulphonamide (Standard) is the analytical standard of Benzenesulphonamide (HY-101087). This product is intended for research and analytical applications. Benzenesulphonamide (Compound 1) is a carbonic anhydrase inhibitor. Benzenesulphonamide exhibits CA II inhibitory activity. Benzenesulphonamide reduces ROS and improves the gene expression of amyloid-β40 and 42. Benzenesulphonamide is beneficial for Alzheimer's disease. Benzenesulphonamide derivatives have anticancer, anti-inflammatory, and anticonvulsant activities. Benzenesulphonamide can be used in the research of Alzheimer's disease, epilepsy, inflammatory diseases, leukemia, melanoma, lung cancer, and colon cancer .
    Benzenesulphonamide (Standard)
  • HY-182429
    NB-533

    		Beta-secretase Cathepsin Amyloid-β Neurological Disease
    NB-533 is an orally active and brain-penetrant BACE-1 inhibitor with a human IC50 of 0.002 μM. NB-533 also inhibits human cathepsin D with an IC50 of 0.001 μM. NB-533 inhibits amyloidogenic amyloid precursor protein (APP) processing and reduces Aβ40 release. NB-533 reduces brain levels of APP metabolite C99 and Aβ40 in transgenic mice. NB-533 can be used for the research of Alzheimer’s disease .
    NB-533
  • HY-180843
    Aβ/tau aggregation-IN-4

    		Tau Protein Amyloid-β Cholinesterase (ChE) Monoamine Oxidase Reactive Oxygen Species (ROS) Neurological Disease
    Aβ/tau aggregation-IN-4 (Compound D21) is an Aβ/tau aggregation inhibitor. Aβ/tau aggregation-IN-4 promotes the degradation of Aβ40/42 (Aβ40, IC50 = 2.151 μM; Aβ42, IC50 = 3.622 μM). Aβ/tau aggregation-IN-4 shows selective AChE inhibition (IC50: 5.56 μM). Aβ/tau aggregation-IN-4 inhibits MAO-A and MAO-B with IC50s of 0.59 μM and 0.09 μM, respectively. Aβ/tau aggregation-IN-4 suppresses intracellular ROS levels. Aβ/tau aggregation-IN-4 can be used in the research of Alzheimer's disease .
    Aβ/tau aggregation-IN-4
  • HY-P991866
    BI 1034020

    		Amyloid-β Neurological Disease
    BI 1034020 is a humanized nanobody, targeting two different epitopes of Aβ ( Aβ40 and Aβ42) with high affinity. BI 1034020 reduces the level of free Ab peptide in plasma and thus prevent the formation of new Aβ plaques and clear existing plaques. BI 1034020 can be used for Alzheimer’s disease research .
    BI 1034020
  • HY-128391
    AZ1136

    		γ-secretase Amyloid-β Neurological Disease
    AZ1136 is a highly selective γ-secretase modulator (GSM). AZ1136 reduces the levels of Aβ42 and Aβ40, with its IC50 being 990 and 1400 nM. AZ1136 increases the levels of Aβ39 and Aβ37, but does not affect Aβ38. AZ1136 can be used for the study of Alzheimer's disease .
    AZ1136
  • HY-18157
    SCH 900229

    		Amyloid-β Neurological Disease
    SCH 900229 is a potent γ-secretase inhibitor with selective activity against PS1. The Aβ40 IC50 value of SCH 900229 is 1.3 nM, showing its excellent ability in reducing Aβ. SCH 900229 has shown good Aβ-lowering effects after oral administration in preclinical animal models. SCH 900229 has been advanced to human clinical trials for further development of compounds for the inhibition of Alzheimer's disease .
    SCH 900229
  • HY-180842
    MAO-B-IN-50

    		Monoamine Oxidase Amyloid-β Tau Protein Cholinesterase (ChE) Neurological Disease
    MAO-B-IN-50 (Compound C20) is a selective MAO-B inhibitor with an IC50 value of 0.06 μM. MAO-B-IN-50 shows good inhibitory effects on the aggregation of Aβ40/42 and Tau proteins, with overall IC50 values around 1 μM. MAO-B-IN-50 exhibits potent and selective AChE inhibition (IC50 = 1.78 μM). MAO-B-IN-50 can be used in the research of Alzheimer's disease .
    MAO-B-IN-50
  • HY-P11677
    CPO_Aβ17-21P

    		Neurological Disease
    CPO_Aβ17-21P is a apoE/Aβ interaction inhibitor with an IC50 of 1.02 nM. CPO_Aβ17-21P significantly inhibits ApoE4-mediated aggregation of Aβ40 and Aβ42. CPO_Aβ17-21P significantly improves cognitive function and comprehensively alleviates Alzheimer's disease (AD)-related pathologies in mouse models. CPO_Aβ17-21P is applicable to the research of AD .
    CPO_Aβ17-21P
  • HY-181861
    AChE/MAO-B-IN-9

    		Cholinesterase (ChE) Monoamine Oxidase Amyloid-β Tau Protein Neurological Disease
    AChE/MAO-B-IN-9 (Compound E12) is an orally active, selective, reversible, non-competitive AChE and MAO-B inhibitor, with an IC50 of 0.156 μM against electric eel AChE. AChE/MAO-B-IN-9 inhibits Aβ40/42 fibril formation, promotes Aβ fibril depolymerization, and inhibits Tau protein fibril formation. AChE/MAO-B-IN-9 exerts antioxidant and neuroprotective effects, and improves scopolamine (HY-N0296)-induced memory impairment in mice. AChE/MAO-B-IN-9 can be used for the research of Alzheimer's disease .
    AChE/MAO-B-IN-9
  • HY-12723R
    Apomorphine (Standard)

    (-)-Apomorphine (Standard)

    		 Reference Standards Dopamine Receptor Monoamine Oxidase Reactive Oxygen Species (ROS) JNK ERK Amyloid-β Tau Protein MMP Neurological Disease Inflammation/Immunology Endocrinology Cancer
    Apomorphine ((-)-Apomorphine) (Standard) is the analytical standard of Apomorphine (HY-12723). This product is intended for research and analytical applications. Apomorphine is a potent dopamine receptor agonist. Apomorphine also inhibit MAO-A and MAO-B. Apomorphine exerts neuroprotective effect and can relax rat corpus cavernosum. Apomorphine can inhibit ROS production, DNA fragmentation and inibit JNK and ERK1/2 phosphorylation. Apomorphine can enhance degradation of intracellular Aβ40 and Aβ42, reduces tau protein levels and inhibit MMP-9 expression. Apomorphine is a highly potent radical scavenger and iron chelator. Apomorphine can be used for the researches of dementia, parkinson's disease, alzheimer disease, breast carcinoma, and erectile dysfunction .
    Apomorphine (Standard)
  • HY-182304
    CLR01 sodium

    		Amyloid-β α-synuclein Amylin Receptor Tau Protein SOD Neurological Disease
    CLR01 sodium is a blood-brain barrier-permeable anti-aggregation agent. CLR01 sodium inhibits the de novo aggregation of Amyloid-β 40/42, α-synuclein, IAPP, tau protein and SOD1. CLR01 sodium reduces amyloid plaque burden in the cortex of triple-transgenic mice and improves the memory and motor abilities of these mice. CLR01 sodium can be used in research related to Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) .
    CLR01 sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: